These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11108433)

  • 21. Influence of lipophilicity on the diffusion of cephalosporins into the cerebrospinal fluid.
    Radouane A; Péhourcq F; Tramu G; Creppy EE; Bannwarth B
    Fundam Clin Pharmacol; 1996; 10(3):309-13. PubMed ID: 8836706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of the third generation cephalosporins.
    Balant L; Dayer P; Auckenthaler R
    Clin Pharmacokinet; 1985; 10(2):101-43. PubMed ID: 3888488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of third-generation cephalosporins in the treatment of bacterial meningitis.
    Modai J
    Chemioterapia; 1986 Oct; 5(5):313-8. PubMed ID: 3791477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third generation cephalosporins.
    Donowitz GR
    Infect Dis Clin North Am; 1989 Sep; 3(3):595-612. PubMed ID: 2671141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of gram-negative bacterial meningitis in term neonates with third generation cephalosporins plus amikacin.
    Dellagrammaticas HD; Christodoulou C; Megaloyanni E; Papadimitriou M; Kapetanakis J; Kourakis G
    Biol Neonate; 2000 Mar; 77(3):139-46. PubMed ID: 10729716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Studies on cerebrospinal fluid penetration of cefpirome in adult with meningitis].
    Munemoto S; Soma M; Kuroda E; Hamada Y; Nakada M
    Jpn J Antibiot; 1996 Jun; 49(6):658-62. PubMed ID: 8776632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of dosing schedules and cerebrospinal fluid bactericidal activity on the therapy of bacterial meningitis.
    Scheld WM; Tauber MG; Zak O; Sande MA
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():303-12. PubMed ID: 3980333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concentrations of cefoperazone in cerebrospinal fluid during bacterial meningitis.
    Cable D; Overturf G; Edralin G
    Antimicrob Agents Chemother; 1983 May; 23(5):688-91. PubMed ID: 6223578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis.
    Andes DR; Craig WA
    Infect Dis Clin North Am; 1999 Sep; 13(3):595-618. PubMed ID: 10470557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Transferability of cefozopran to cerebrospinal fluid in rabbits with meningitis caused by Staphylococcus aureus].
    Haruta T; Okura K; Kuroki S; Nikami H; Kobayashi Y
    Jpn J Antibiot; 1996 May; 49(5):517-21. PubMed ID: 8752865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolones in the Treatment of Meningitis.
    Cottagnoud P; Täuber MG
    Curr Infect Dis Rep; 2003 Aug; 5(4):329-336. PubMed ID: 12866985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics of antibiotics in experimental bacterial meningitis--two sides to rapid bacterial killing in the cerebrospinal fluid.
    Täuber MG; Sande MA
    Scand J Infect Dis Suppl; 1990; 74():173-8. PubMed ID: 2097706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The selection and use of cephalosporins: a review.
    Klein NC; Cunha BA
    Adv Ther; 1995; 12(2):83-101. PubMed ID: 10150326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.
    Dacey RG; Sande MA
    Antimicrob Agents Chemother; 1974 Oct; 6(4):437-41. PubMed ID: 4157341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology and cerebrospinal fluid penetration of moxalactam in children and dosage recommendations.
    Kaplan SL; Mason EO; Kvernland SJ; Calaway EL; Feigin RD
    Rev Infect Dis; 1982; 4 Suppl():S597-602. PubMed ID: 6218570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.
    Perry TR; Schentag JJ
    Clin Pharmacokinet; 2001; 40(9):685-94. PubMed ID: 11605716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on serum and cerebrospinal fluid levels of cephacetrile in neonates.
    Windorfer A; Gasteiger U
    Infection; 1977; 5(4):242-7. PubMed ID: 598930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Transferability of cefpirome to cerebrospinal fluid of rabbits with meningitis caused by Staphylococcus aureus].
    Haruta T; Okura K; Kuroki S; Kobayashi Y
    Jpn J Antibiot; 1991 Jan; 44(1):58-61. PubMed ID: 2041148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae.
    Lodise TP; Nau R; Kinzig M; Jones RN; Drusano GL; Sörgel F
    Diagn Microbiol Infect Dis; 2007 Aug; 58(4):445-52. PubMed ID: 17512154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.